Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 15 studies | 31% ± 12% | |
peripheral blood | 14 studies | 22% ± 6% | |
brain | 8 studies | 34% ± 17% | |
intestine | 4 studies | 23% ± 7% | |
uterus | 4 studies | 24% ± 8% | |
prostate | 4 studies | 21% ± 5% | |
kidney | 3 studies | 21% ± 4% | |
eye | 3 studies | 22% ± 5% | |
heart | 3 studies | 19% ± 3% | |
adipose | 3 studies | 24% ± 5% | |
lymph node | 3 studies | 25% ± 10% | |
breast | 3 studies | 23% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 16171.31 | 578 / 578 | 100% | 129.73 | 1154 / 1155 |
esophagus | 100% | 4521.90 | 1443 / 1445 | 100% | 124.27 | 183 / 183 |
stomach | 100% | 3990.60 | 358 / 359 | 100% | 101.24 | 286 / 286 |
breast | 100% | 10289.53 | 459 / 459 | 100% | 94.70 | 1114 / 1118 |
intestine | 100% | 5136.48 | 966 / 966 | 99% | 102.04 | 524 / 527 |
bladder | 100% | 4485.05 | 21 / 21 | 99% | 97.09 | 501 / 504 |
prostate | 100% | 5253.32 | 244 / 245 | 100% | 102.41 | 501 / 502 |
thymus | 100% | 6017.91 | 652 / 653 | 99% | 114.47 | 601 / 605 |
uterus | 100% | 5014.85 | 170 / 170 | 99% | 107.64 | 454 / 459 |
ovary | 100% | 4117.54 | 180 / 180 | 99% | 62.13 | 425 / 430 |
adrenal gland | 100% | 5125.96 | 258 / 258 | 97% | 59.81 | 223 / 230 |
kidney | 97% | 2838.69 | 86 / 89 | 98% | 88.32 | 887 / 901 |
brain | 92% | 3009.09 | 2438 / 2642 | 100% | 117.39 | 703 / 705 |
skin | 100% | 5870.52 | 1809 / 1809 | 90% | 50.84 | 423 / 472 |
liver | 92% | 4153.52 | 209 / 226 | 96% | 66.73 | 389 / 406 |
pancreas | 84% | 2167.51 | 275 / 328 | 99% | 102.79 | 176 / 178 |
adipose | 100% | 11261.23 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 85.17 | 29 / 29 |
spleen | 100% | 13850.93 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 142.77 | 45 / 45 |
heart | 100% | 6201.46 | 859 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 5094.61 | 1327 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 16753.88 | 923 / 929 | 0% | 0 | 0 / 0 |
muscle | 95% | 3299.84 | 761 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 44% | 16.50 | 35 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0009615 | Biological process | response to virus |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0098586 | Biological process | cellular response to virus |
GO_0060333 | Biological process | type II interferon-mediated signaling pathway |
GO_1902004 | Biological process | positive regulation of amyloid-beta formation |
GO_0038196 | Biological process | type III interferon-mediated signaling pathway |
GO_0001774 | Biological process | microglial cell activation |
GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
GO_1900222 | Biological process | negative regulation of amyloid-beta clearance |
GO_0048143 | Biological process | astrocyte activation |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0004906 | Molecular function | type II interferon receptor activity |
GO_0019955 | Molecular function | cytokine binding |
GO_0005515 | Molecular function | protein binding |
GO_0004896 | Molecular function | cytokine receptor activity |
Gene name | IFNGR1 |
Protein name | Interferon gamma receptor 1 isoform 1 Interferon-gamma receptor alpha chain Interferon gamma receptor 1 (IFN-gamma receptor 1) (IFN-gamma-R1) (CDw119) (Interferon gamma receptor alpha-chain) (IFN-gamma-R-alpha) (CD antigen CD119) Interferon gamma receptor 1 isoform 2 Truncated interferon-gamma receptor 1 Interferon gamma receptor 1 |
Synonyms | |
Description | FUNCTION: Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation . Associates with transmembrane accessory factor IFNGR2 to form a functional receptor . Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signaling components JAK1 and JAK2. In turn, activated JAK1 phosphorylates IFNGR1 to form a docking site for STAT1. Subsequent phosphorylation of STAT1 leads to dimerization, translocation to the nucleus, and stimulation of target gene transcription . STAT3 can also be activated in a similar manner although activation seems weaker. IFNGR1 intracellular domain phosphorylation also provides a docking site for SOCS1 that regulates the JAK-STAT pathway by competing with STAT1 binding to IFNGR1 (By similarity). . |
Accessions | ENST00000696695.1 ENST00000644894.1 A0A8Q3WLI2 A5HJZ4 ENST00000367739.9 [P15260-1] ENST00000645045.1 ENST00000646036.1 ENST00000414770.6 A0A8Q3SJH3 A0A2R8Y7R1 Q5TFC9 ENST00000696698.1 A0A2R8Y4U4 A0A2R8YFL3 ENST00000696697.1 A0A8Q3SJ27 ENST00000458076.6 A0A8Q3WLI6 ENST00000647124.1 ENST00000696694.1 ENST00000645753.1 P15260 ENST00000642390.1 Q7Z687 ENST00000646898.1 A0A0S2Z3R7 A0A2R8Y792 ENST00000696696.1 A0A8Q3WLG6 ENST00000696693.1 A0A0S2Z3Y2 A0A8Q3SIW7 E5QBZ2 ENST00000643119.1 ENST00000696699.1 |